• Hubert Aiwanger was born in 1971 and grew up in Rahstorf in the district of Landshut in Lower Bavaria.
• After passing his A levels and finishing his military service, in 1991, he began to study agricultural sciences at the University of Applied Sciences of Weihenstephan.
• In 1995, Hubert Aiwanger successfully finished his studies as a graduate agricultural engineer and started working at his family’s farm.
• Since 2006, Hubert Aiwanger has been Bavarian Chairman and since 2010 German Chairman of the party of FREIE WÄHLER.
• In 2008, Hubert Aiwanger was elected for the first time to the Bavarian State Parliament; until October 2018, he was Group Chairman of the parliamentary group of FREIE WÄHLER in the Bavarian State Parliament.
• Since November 12, 2018, Hubert Aiwanger has been Bavarian State Minister of Economic Affairs, Regional Development and Energy as well as Deputy Bavarian Prime Minister.

Dr. Eduardo Beltrán, a trailblazer in human data science, focuses on neuroimmunology and immuno-oncology. With a global perspective, he adeptly navigates diverse healthcare landscapes, embracing regulatory changes to foster innovation. Dr. Beltrán's expertise lies in merging research excellence with regulatory adaptability, driving RWD partnerships for impactful insights. www.linkedin.com/in/eduardo-beltr%C3%A1n-64ab7739/

Chris is a computer scientist turned bioinformatician with a passion for systematically modelling biological mechanisms through machine learning. His path towards reaching this goal led him to contribute and push the community of learned protein sequence representations in order to find new, principled ways to describe biological entities. Bio-sequence representation learning, for instance through transformer models, is today an established field in bioinformatics with flourishing frameworks and impactful research applications, like the prediction of protein 3D structure from just an input sequence. Chris remains focused on trying to address problems for which data and intuition remain scarce, for instance those allowing to design new proteins with therapeutic or industrial use.

www.linkedin.com/in/sacdallago

Dr. Tilman Flock leads Life Science Engagements at Palantir Technologies, focusing on innovative data strategies and digital transformation specialized in biomedical R&D and biomanufacturing. His expertise bridges biomedical research with AI and digital technologies. He brings a decade of academic experience in computational and experimental biotechnology, contributing to high-impact journals, before transitioning into the tech industry six years ago.
Earlier in his career, Dr. Flock was a Junior Research Fellow at the University of Cambridge and ETH Zurich, after earning his PhD in Computational Biology at the University of Cambridge, where he was associated with the MRC Laboratory of Molecular Biology and Trinity College. His research was recognized with the Max Perutz Award. Dr. Flock's pivotal moment to transition into AI and computational research occurred during his Master’s studies with Prof. Frances Arnold at the California Institute of Technology, where he augmented experimental protein engineering with computational predictions. He completed his undergraduate studies in Molecular Biotechnologies at the Technical University of Munich, specialising in Biophysics, Molecular Medicine, and Synthetic Biology.

www.linkedin.com/in/tilman-flock/

"Hype vs. Impact: GenAI's true potential in drug discovery requires seamless integration of companies' data, tools, and knowledge to operationalise real-world workflows that drive transformative outcomes.”

Selina obtained her medical degree at the Charité University Hospital in Berlin, and started her professional career at the Berlin Institute of Health (BIH) Center for Regenerative Therapies with a doctoral thesis on the expansion and differentiation of human induced pluripotent stem cells. Subsequently, she worked as an assistant physician at the Institute of Pathology of the Charité University Hospital before moving to Bioscience Valuation, a life science consultancy, where she performed commercial assessments and valuations of early- and late-stage assets and advised clients on their R&D strategy. After completing her MBA at the Cambridge Judge Business School, Selina pivoted into the world of Venture Capital; she currently works as a Life Science Associate at Oxford Science Enterprises, where she identifies new investment opportunities, creates new biotech businesses, and supports the existing portfolio.
LinkedIn: www.linkedin.com/in/selina-greuel-335a71216/

Dietmar Harhoff is Director at the Max Planck Institute for Innovation and Competition and Professor for Entrepreneurship and Innovation at the Ludwig-Maximilians-Universität (LMU) Munich. His research focuses on innovation, entrepreneurship, intellectual property, industrial economics, and economic policy.
Before assuming his current position at the Max Planck Institute, he was Full Professor and Director of the Institute for Innovation Research, Technology Management and Entrepreneurship at LMU Munich (1998–2013). From 2001 to 2019, he established and ran the LMU Entrepreneurship Center together with partners from business and industry. In 2010, Dietmar Harhoff co-founded the German Accelerator Program. He has also co-founded start-ups and is a seed investor in young firms. He has served in advisory functions to private and public organizations at various times. From 2007 to 2019, he was Chairman of the Commission of Experts for Research and Innovation (EFI), which presents annual reports on research, innovation and technological performance to the German Chancellor. In 2019, he was appointed chair of the Commission for the establishment of the German Agency for Disruptive Innovation (SPRIND). He is now member of the SPRIND supervisory board.
Dietmar Harhoff is elected member of the German Academy of Science and Engineering (acatech), the German National Academy of Sciences Leopoldina, and the Bavarian Academy of Sciences and Humanities (BAdW).
de.linkedin.com/in/dietmar-harhoff-40811b

Ralf Huss, MD, PhD is currently managing director of the BioM Biotech Cluster Development GmbH in Planegg near Munich. Until the end of 2022, he was the founding Director of the Institute of Digital Medicine (IDM) and Professor of Pathology and Molecular Diagnostics at the University Hospital in Augsburg, Germany. 

Before joining the Medical faculty in Augsburg in 2020, Dr. Huss spent many years in the pharmaceutical and diagnostic industry at Roche and AstraZeneca as Global Head of Histopathology and Tissue Biomarker, also developing image-based algorithms to predict therapy response based on the application of machine intelligence.  

He also founded some biotech enterprises, held appointments as Adjunct professor at the Institute of Regenerative Medicine at Wake Forest, Winston Salem (NC), and is still lecturer on “Biomaterials and Bioresponsive Polymers” at the Faculty of Chemistry, Technical University Munich, Germany. Dr. Huss is also honorary professor at Systems Biology Ireland, University College Dublin. In his almost 30 years in academic and industrial research, Dr. Huss authored more than 180 papers on cancer and stem cell research as well as the use on artificial intelligence in digital medicine.

Kei W. Müller studied mechanical engineering at TUM with a scholarship of the Studienstiftung des deutschen Volkes, specialized in numerical biomechanics, and did his PhD at the Institute for Computational Mechanics with Prof. Wolfgang A. Wall. He received the Award of the Faculty of Mechanical Engineering for his dissertation on modeling and simulation of the self-assembly and mechanics of intracellular protein fiber networks.
After a two-year postdoc in numerical methods development and high-performance computing at the Lawrence Livermore National Lab, he returned to Germany to co-found Ebenbuild, which creates AI & physics-based digital twins of the lungs, and has been its CEO since.
www.linkedin.com/in/kei-wieland-mueller/

"The biggest pharma need that digitalization can solve is neither (AI-based) drug discovery nor (decentralized) clinical trials. At $520bn, improving patient adherence is by far the biggest opportunity."
www.linkedin.com/in/manuelopitz/

since Jan 2015 Munich Leukemia Laboratory
Senior Specialist Hematology
Coordination of diagnostic workflows
External consulting
Research (Genetics, AI/machine learning)
Head of cytomorphology department (since May 2019)
Member of Management Board (since Jan 2017)
Strategic Business Development
Head of Customer Care/CRM (since Jan 2020)
Jan 2013 – Dec 2014 St. Hedwig-Hospital Berlin
Senior Physician
Head of Department Hematology + Oncology
Jan 2007 – Dec 2012 University Hospital Muenster
Specialist Internal Medicine, Specialist Hematology/Oncology
Jan 2004 – Dec 2006 University Hospital Essen, West German Cancer Center Intern/assistant physician Research associate
Jan 2000 – Jan 2003 4CastSystems GmbH
Junior Consultant (Investment Research Biotechnology)
de.linkedin.com/in/dr-christian-pohlkamp-a2539115a

www.linkedin.com/in/sidhyansh-saxena-9245a952/

Dr Julia Schaft holds a PhD in biology and completed her doctorate at the Justus Liebig University Giessen and the European Molecular Biology Laboratory (EMBL) Heidelberg in 2002. Julia initially worked in the research department of an in vitro fertilisation clinic in Sydney Australia with human embryonic stem cells, but then moved into increasingly responsible management positions in which she both led scientific projects and worked in the field of legislative and ethical research regulation. In 2016, Julia joined BioRN as a project manager, led BMBF-funded internationalisation projects and played a key role in the strategic realignment of the BioRN Cluster.
Since 2018 Julia is Managing Director of BioRN, managing a network of key innovation stakeholders and advancing the Rhine-Neckar-region into one of the worlds leading life science clusters.
Julia was appointed to the supervisory board of WMT Therapeutics, a start-up in the field of oncology, and to the supervisory board of the European Funding Consortium EIT Health. Julia has been the spokesperson for the Council of German BioRegions since 2023.

Dr. Ariel Dora Stern is the Alexander von Humboldt Professor for Digital Health, Economics and Policy at the Hasso Plattner Institute. Her research focuses on technology management and innovation in health care, using methods from econometrics and data science to study the regulation, strategy, and economics of health care, with a focus on emerging health care technologies and delivery modalities.

linkedin.com/in/arieldora

"Shifting from experience and eminence to big data and evidence will soon shift therapies from one-size-fits-all to patient individual therapies with improved reported patient outcome."

Linkedin Jörg Traub

Joanna Wardzinski heads Global Partnerships and Strategic Programs in Healthcare. She focuses on fostering partnerships and building channel capacity to enable access and delivery of person centered care and improved healthcare outcomes through the digitization and use of healthcare data. She is also responsible for overseeing key strategic global initiatives (e.g. workforce development). Joanna's journey with AWS began in 2017, where she initially oversaw strategic planning and investment for AWS EMEA Public Sector. During this period, she co-developed the healthcare vertical's business case, subsequently transitioning to lay the groundwork for the practice on an international scale. Joanna has been in the digital technology field since 2014, leveraging her INSEAD MBA as a launch pad to a career dedicated to Tech for Good. Her prior roles at Microsoft and in the Canadian federal government ranged from amendments to the Investment Canada Act to organizing Commercial Missions to India. Joanna is a dual citizen of Canada and Poland, has lived in 7 different countries, and currently resides in Germany.

"In today's healthcare landscape, the key to unlocking the full potential of personalized health lies in the effective utilization of data. However, up to 97% of health data often remains inaccessible due to siloes or challenges in data formats."

Roman Werner is the Managing Director of the TUM Venture Lab Food-Agro-Biotech (FAB) at the Technical University of Munich (TUM). The FAB is a university start-up center at TUM and has its home at the School of Life Sciences Weihenstephan. Here he oversees a wide variety of start-up activities and ventures with technical know-how as well as access to important infrastructure. He studied brewing and beverage technology from 2008 to 2014 and processed with a Ph.D. at TUM. From 2018, he also took on several research projects in the field of food technology as a regular scientist. His main research area is process engineering and specifically cleaning, disinfection as well as food safety in the beverage and food industry. Other research areas include novel sensor technologies as well as digitization concepts that drive the transformation of the food industry into the age of digitization.

www.linkedin.com/in/roman-werner-109602179/

"Commercializing biotech research boosts universities, attracts more talent, fosters industry ties, and enhances the practical impact of academic projects."

Justus has almost a decade of Digital Health and AI work experience with insurance, pharma and medtech companies internationally and conducted his PhD at the chair of Experimental Bioinformatics at the Technical University Munich about AI implementation in healthcare. A special focus area is AI for major disease areas as for example Diabetes.

“Artificial Intelligence in Healthcare has its breakthrough in Germany with the newly published laws under the umbrella of the EHDS”